secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-07-26T23:59:59+00:00
Accession:  0001140361-22-026910
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics secures $60M credit line from chairman; CEO extends stock compensation
--------------------------------------------------------------------------------

- $60M unsecured line of credit from Chairman Richard Uihlein through July 31, 2024; principal & interest due Jan 31, 2026.
- Interest at AFR (2.84%) + 2%; conversion price at closing price but not below $3.00 per share.
- Initial warrant for 500k shares at $5.00; up to 1.2M additional warrants at 150% of draw closing price (floor $3, cap $10).
- CEO Joel Lewis extends 80% stock compensation through Dec 2023; employment term extended to Dec 2024.
- Proceeds expected to fund operations through 2024; NAVIGATE phase 2b results expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/0001140361-22-026910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-026910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer